{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:10Z","timestamp":1787016970442,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1136\/ard.2009.115378","type":"journal-article","created":{"date-parts":[[2010,4,21]],"date-time":"2010-04-21T20:34:50Z","timestamp":1271882090000},"page":"945-948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Cytokines in Sj\u00f6gren's syndrome: potential therapeutic targets"],"prefix":"10.1016","volume":"69","author":[{"given":"Nienke","family":"Roescher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor G","family":"Illei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2009.115378_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1601-0825.2009.01582.x","article-title":"Cytokines in Sj\u00f6gren's syndrome","volume":"15","author":"Roescher","year":"2009","journal-title":"Oral Dis"},{"key":"10.1136\/ard.2009.115378_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/gene.2009.20","article-title":"Peripheral blood gene expression profiling in Sj\u00f6gren's syndrome","volume":"10","author":"Emamian","year":"2009","journal-title":"Genes Immun"},{"key":"10.1136\/ard.2009.115378_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/29.1.50","article-title":"Immunoreactive circulating alpha-interferon is low in Sj\u00f6gren's syndrome","volume":"29","author":"Shiozawa","year":"1990","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2009.115378_bib4","first-page":"367","article-title":"Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sj\u00f6gren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine","volume":"14","author":"Ferraccioli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2009.115378_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/rheumatology\/32.1.52","article-title":"A preliminary study on the interferon-alpha treatment for xerostomia of Sj\u00f6gren's syndrome","volume":"32","author":"Shiozawa","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2009.115378_bib6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2460\/ajvr.2005.66.164","article-title":"Systemic effects of interferons after oral administration in animals and humans","volume":"66","author":"Cummins","year":"2005","journal-title":"Am J Vet Res"},{"key":"10.1136\/ard.2009.115378_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/jir.1998.18.255","article-title":"Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sj\u00f6gren's syndrome","volume":"18","author":"Shiozawa","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"10.1136\/ard.2009.115378_bib8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1089\/107999099313497","article-title":"Treatment of primary Sj\u00f6gren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group","volume":"19","author":"Ship","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1136\/ard.2009.115378_bib9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.11199","article-title":"Treatment of primary Sj\u00f6gren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results","volume":"49","author":"Cummins","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.115378_bib10","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sj\u00f6gren's syndrome: a pilot study","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.115378_bib11","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.115378_bib12","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.115378_bib13","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.115378_bib14","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/ard.2007.077891","article-title":"Lack of efficacy of etanercept in Sj\u00f6gren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation","volume":"67","author":"Moutsopoulos","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.115378_bib15","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","article-title":"Augmented interferon-alpha pathway activation in patients with Sj\u00f6gren's syndrome treated with etanercept","volume":"56","author":"Mavragani","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.115378_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/gene.2009.20","article-title":"Peripheral blood gene expression profiling in Sj\u00f6gren's syndrome","volume":"10","author":"Emamian","year":"2009","journal-title":"Genes Immun"},{"key":"10.1136\/ard.2009.115378_bib17","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj\u00f6gren's syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.2009.115378_bib18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/art.24557","article-title":"Neutralization of interferon-alpha\/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus","volume":"60","author":"Yao","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.115378_bib19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1601-0825.2009.01582.x","article-title":"Cytokines in Sj\u00f6gren's syndrome","volume":"15","author":"Roescher","year":"2009","journal-title":"Oral Dis"},{"key":"10.1136\/ard.2009.115378_bib20","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/eji.200738013","article-title":"Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways","volume":"38","author":"Ittah","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1136\/ard.2009.115378_bib21","series-title":"Belimumab, a Blys-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study","author":"Navarra","year":"2009"},{"key":"10.1136\/ard.2009.115378_bib22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1136\/ard.2009.115378_bib23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus \u2013 safety, preliminary efficacy and impact on circulating plasma cells","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.115378_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03191127","article-title":"Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis","volume":"31","author":"Tak","year":"2006","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1136\/ard.2009.115378_bib25","first-page":"515","article-title":"ABT-874, a fully human monoclonal anti-IL-12\/IL-23 antibody for the potential treatment of autoimmune diseases","volume":"9","author":"Ding","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1136\/ard.2009.115378_bib26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"10.1136\/ard.2009.115378_bib27","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.coi.2006.09.008","article-title":"The IL-23\/Th (17) axis: therapeutic targets for autoimmune inflammation","volume":"18","author":"Kikly","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"10.1136\/ard.2009.115378_bib28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2353\/ajpath.2009.090319","article-title":"Systemic and local interleukin-17 and linked cytokines associated with Sj\u00f6gren's syndrome immunopathogenesis","volume":"175","author":"Katsifis","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1136\/ard.2009.115378_bib29","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/art.23214","article-title":"Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sj\u00f6gren's syndrome: findings in humans and mice","volume":"58","author":"Nguyen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.115378_bib30","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.4049\/jimmunol.181.4.2898","article-title":"Identification of IL-18 and Th17 cells in salivary glands of patients with Sj\u00f6gren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18","volume":"181","author":"Sakai","year":"2008","journal-title":"J Immunol"},{"key":"10.1136\/ard.2009.115378_bib31","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1089\/104303403322542257","article-title":"Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sj\u00f6gren's syndrome","volume":"14","author":"Kok","year":"2003","journal-title":"Hum Gene Ther"},{"key":"10.1136\/ard.2009.115378_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2005.038232","article-title":"Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome","volume":"65","author":"Lodde","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724194472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724194472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2009.115378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T09:07:12Z","timestamp":1736068032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724194472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0003496724194472"],"URL":"https:\/\/doi.org\/10.1136\/ard.2009.115378","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokines in Sj\u00f6gren's syndrome: potential therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2009.115378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}